1291487-26-7

Basic information

• Product Name: 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde
• Synonyms: 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde;Benzaldehyde, 5-broMo-2-fluoro-3-(trifluoroMethyl)-
• CAS NO: 1291487-26-7
• Molecular Formula: C₈H₃BrF₄O
• Molecular Weight: 271.0064328
• Mol File: 1291487-26-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 222.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.748±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde(1291487-26-7)
• EPA Substance Registry System: 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde(1291487-26-7)

Safety Data

• Hazardous Substances Data: 1291487-26-7(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde is a chemical compound with the molecular formula C8H4BrF4O. It is a benzaldehyde derivative with a bromine and fluorine atom attached to the benzene ring, as well as a trifluoromethyl group. 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde is used in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of dyes and pigments. Additionally, 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde has potential applications in medicinal and material chemistry due to its unique chemical structure and reactivity. Overall, this compound has various industrial and research applications, making it an important chemical in the field of organic chemistry.

Upstream product

• 393-37-3 5-bromo-2-fluorobenzotrifluoride 
• 68-12-2 N,N-dimethyl-formamide 

Relevant articles and documents

INHIBITING HUMAN INTEGRIN α4β7

Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.